by McDermott + Bull | Sep 26, 2026 | Ken Dropiewski, Dani Rone, Ken Dropiewski Placement Announcement
McDermott + Bull has successfully placed Jeffrey DellaFranco as Vice President of Sales at Galvanize Therapeutics. In this role, Jeff will lead the company’s U.S. sales organization and support its transition to a procedure-focused commercial model. He will focus on...
by McDermott + Bull | Sep 22, 2026 | Ken Dropiewski, Ken Dropiewski Placement Announcement, Michael Matranga
McDermott + Bull has successfully placed Rhonda Robb as Chief Executive Officer at ArchCath. In this role, Rhonda will lead the company through its next phase of growth, with responsibility for advancing its financing, clinical, regulatory, and commercialization...
by McDermott + Bull | Sep 21, 2026 | Article, Ken Dropiewski, Ken Dropiewski Article
Most CEOs I work with are exceptional at vision. They can articulate where the company is going, why it matters, and what winning looks like. What they struggle to articulate is why they’re still approving vendor contracts, resolving team conflicts, and sitting...
by McDermott + Bull | Aug 24, 2026 | Ken Dropiewski, Investor Insights, Video
McDermott + Bull Partner Ken Dropiewski sits down with Jan Garfinkle, Founder & Managing Partner of Arboretum Ventures, and Jeff Terrell, Managing Partner, to discuss their perspectives on healthcare investing and the evolving venture capital landscape. Jan shares...
by McDermott + Bull | Aug 11, 2026 | Ken Dropiewski, Ken Dropiewski Placement Announcement, Michael Matranga
McDermott + Bull has successfully placed David Vort as Chief Commercial Officer at Caristo Diagnostics. In this role, David will lead the company’s U.S. commercial strategy, with responsibility for accelerating revenue, advancing market access and reimbursement...
by McDermott + Bull | Jul 8, 2026 | Ken Dropiewski Placement Announcement, Christiana Chan, Ken Dropiewski
McDermott + Bull has successfully placed Chris Wolff as Senior Vice President, Market Development at FIRE1 Medical. In this role, Chris will lead the company’s U.S. market development strategy as FIRE1 advances toward commercialization of its breakthrough heart...
